Some providers featured on this site may compensate us. This may affect the order and placement of listings but does not influence our editorial ratings or reviews.
TopWeightLoss.ioTreatmentsHub
Science6 min read

Veradermics' VDPHL01: The Hair Loss Pill Everyone's Searching (2026)

VDPHL01 is an extended-release oral minoxidil in late-stage trials - the potential first FDA-approved hair loss pill for women and men. What the company reports, the timeline, and what you can do today.

By TreatmentsHub StaffUpdated August 30, 2026

Key takeaways

  • VDPHL01 is Veradermics' extended-release oral minoxidil, aiming to become the first FDA-approved oral prescription treatment for pattern hair loss.
  • The company reports positive Phase 2/3 results in men (April 2026) and positive early results in women, with major readouts expected in late 2026 and the first half of 2027.
  • It is not approved and not available yet - trial success so far is the company's own reporting, and late-stage trials can still surprise.
  • The active ingredient, minoxidil, is already prescribable today: oral minoxidil is available off-label through hair-loss telehealth providers.

What is VDPHL01?

VDPHL01 is an extended-release oral minoxidil tablet developed by Veradermics, a clinical-stage dermatology company - and the reason searches for it are spiking is its run of trial news. Minoxidil itself is the most familiar name in hair loss, but today's approved products are topical; oral minoxidil is widely prescribed for hair loss only off-label. VDPHL01 is the attempt to change that: run the full FDA trial program and become the first approved oral prescription treatment for pattern hair loss - in both men and women, a market the company estimates at 50 million men and 30 million women in the US alone.

What have the trials shown so far?

Per the company's own announcements - the honest framing, since peer review and FDA review are still ahead: the Phase 2/3 "302" trial in male pattern hair loss reported positive results in April 2026, described as early, consistent and robust hair growth, and its CEO has claimed faster, stronger growth versus standard minoxidil. On the women's side, an open-label Phase 2 study reported rapid-onset growth, and enrollment is complete in a 556-participant registration-directed Phase 2/3 trial. The catch to keep in view: these are company-reported topline results, and late-stage programs can and do surprise - which is exactly what the remaining readouts are for.

When could it actually be available?

Not soon enough for anyone shedding hair today. The company's stated timeline puts 12-month male data and a confirmatory Phase 3 readout in late 2026, and the women's registration trial readout in the first half of 2027 - and only after successful readouts does an FDA submission and review process begin.

Realistically, that puts any approval well down the road. Treat VDPHL01 as a genuinely promising pipeline story to watch, not a reason to wait: untreated pattern loss progresses, and follicles that spend years miniaturizing are harder to rescue later.

What can you do today instead of waiting?

The ingredient at the center of this story is already prescribable. Oral minoxidil is available off-label right now through licensed telehealth providers - our guide to getting oral minoxidil online covers exactly how, and oral vs topical lays out the trade-offs a prescriber weighs. Combined with finasteride where appropriate, that is the evidence-backed toolkit that exists today - compare the providers we rank, with plans from $24.99/month.

If VDPHL01 clears its remaining trials, it will join that toolkit with an FDA label; until then, the treatment conversation belongs with a licensed provider. This article is general information, not medical advice.

Ready to compare weight loss providers?

See how top providers stack up on pricing, medical support, and treatment options.